Adrian Quartel
Chief Tech/Sci/R&D Officer en ZEVRA THERAPEUTICS, INC. .
Perfil
Presently, Adrian Quartel occupies the position of Chief Medical Officer at Zevra Therapeutics, Inc.
In his past career he occupied the position of Head-Medical Affairs at BioMarin Pharmaceutical, Inc., Chief Medical Officer at Adamas Pharmaceuticals LLC and Chief Medical Officer for Acer Therapeutics, Inc.
Adrian Quartel received a doctorate from Erasmus University Rotterdam.
Cargos activos de Adrian Quartel
Empresas | Cargo | Inicio |
---|---|---|
ZEVRA THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 04/01/2024 |
Antiguos cargos conocidos de Adrian Quartel.
Empresas | Cargo | Fin |
---|---|---|
ADAMAS PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 01/02/2022 |
BIOMARIN PHARMACEUTICAL INC. | Chief Tech/Sci/R&D Officer | 01/09/2020 |
ACER THERAPEUTICS INC. | Chief Tech/Sci/R&D Officer | - |
Formación de Adrian Quartel.
Erasmus University Rotterdam | Doctorate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
Empresas cotizadas | 2 |
---|---|
BIOMARIN PHARMACEUTICAL INC. | Health Technology |
ZEVRA THERAPEUTICS, INC. | Health Technology |
Empresas privadas | 2 |
---|---|
Adamas Pharmaceuticals LLC
Adamas Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA. | Health Technology |
Acer Therapeutics, Inc.
Acer Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Acer Therapeutics, Inc. is a pharmaceutical company, which engages in the acquisition, development, and commercialization of therapies for medical needs. Its product pipeline includes Olpruva, Edsivo, and ACER-801. Olpruva is used for the treatment of urea cycle disorders. Edsivo is a type of celiprolol used in treating Vascular Ehlers-Danlos syndrome. ACER-001 treats menopausal related Vasomotor symptoms. The company was founded by Chris Schelling on March 15, 1991 and is headquartered in Newton, MA. | Health Technology |